Treatment of rheumatoid arthritis with rituximab: An update and possible indications

Autoimmunity Reviews

Volumn 5, Issue 7, 2006, Pages 443-448

  De Vita, Salvatore ^a   Quartuccio, Luca ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Lymphoma; Lymphoproliferation; Rheumatoid arthritis; Rituximab; TNF

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE; CLINICAL RESEARCH; DRUG EFFICACY; DRUG SAFETY; GLOMERULONEPHRITIS; HUMAN; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 33747184593     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.02.007     Document Type: Review

References (33)

1. Dörner T., and Burmester G.R. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol 15 (2003) 246-252
2. Zhang Z., and Bridges Jr. S.L. Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum Dis Clin North Am 27 (2001) 335-353
3. Takemura S., Klimiuk P.A., Braun A., Goronzy J.J., and Weyand C.M. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 167 (2001) 4710-4718
4. Protheroe A., Edwards J.C., Simmons A., Maclennan K., and Selby P. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology 38 (1999) 1150-1152
5. Edwards J.C., and Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40 (2001) 205-211
6. De Vita S., Sacco S., Zaja F., Damato R., Gremese E., and Ferraccioli G.F. Pathogenetic role of B cells in rheumatoid synovitis: selective B-cell blockade may lead to clinical response in refractory RA patients. Reumatismo 53 Suppl. 4 (2001) 323
7. De Vita S., Zaja F., Sacco S., De Candia A., Fanin R., and Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46 (2002) 2029-2033
8. Leandro M.J., Edwards J.C., and Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61 (2002) 883-888
9. Emery P., Fleischmann R.M., Filipowicz-Sosnowska A., Schechtman J., Ramos-Remus C., Gomez-Reino J.J., et al. Rituximab in rheumatoid arthritis: a double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 52 Suppl. 9 (2005) S709
10. Mease P., Szechinski J., Greenwald M., Leirisalo-Repo M., Kivitz A., Barile-Fabris L., et al. Improvements in patients reported outcomes over 24 weeks for rituximab with methotrexate in rheumatoid arthritis patients in phase IIb trial (DANCER). Arthritis Rheum 52 Suppl. 9 (2005) S138
11. Fleischmann R.M., Racewicz A.J., Schechtman J., Khraishi M., Ferraccioli G.F., Hessey E., et al. Rituximab efficacy in rheumatoid arthritis is independent of coadministration of glucocorticoids: results from the dose-ranging assessment international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) study. Arthritis Rheum 52 Suppl. 9 (2005) S130-S131
12. van Vollhenhoven R.F., Schechtman J., Szczepanski L.J., Fleischmann R.M., Hazleman B.L., Nash P.T., et al. Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis: results from the dose-ranging assessment international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) study. Arthritis Rheum 52 Suppl. 9 (2005) S711
13. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
14. van der Kolk L.E., Grillo-Lopez A.J., Baars J.W., Hack C.E., and van Oers M.H. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 115 (2001) 807-811
15. Fleischmann R.M., Pavelka K., Baldassare A.R., Martin-Mola E., Chatpar P.C., Nash P.T., et al. Preliminary efficacy results of rituximab retreatment in patients with active rheumatoid arthritis. Arthritis Rheum 52 Suppl. 9 (2005) S131
16. Emery P., Fleischmann R.M., Pavelka K., Kaell A.T., Szechinski J.Z., Hooper M.M., et al. Safety and tolerability of rituximab retreatment in patients with active rheumatoid arthritis. Arthritis Rheum 52 Suppl. 9 (2005) S341
17. Zaja F., De Vita S., Mazzaro C., Sacco S., Damiani D., De Marchi G., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101 (2003) 3827-3834
18. Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology in press [Electronic publication ahead of print, Jan 17].
19. Hochberg M.C., Lebwohl M.G., Plevy S.E., Hobbs K.F., and Yocum D.E. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 34 (2005) 819-836
20. Cohen S.B., Greenwald M., Dougados M.R., Emery P., Furie R., Shaw T.M., et al. Efficacy and safety of rituximab in active RA patients who experienced an inadequate response to one or more anti-TNFα therapies. Arthritis Rheum 52 Suppl. 9 (2005) S677
21. Keystone E.C., Burmester G.R., Furie R., Loveless J.E., Emery P., Cravets M.W., et al. Improved quality of life with rituximab plus methotrexate in patients with active rheumatoid arthritis who experienced inadequate response to one or more anti-TNFα. Arthritis Rheum 52 Suppl. 9 (2005) S141-S142
22. Leandro M.J., Cambridge G., Edwards J.C., Ehrenstein M.R., and Isenberg D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 44 (2005) 1542-1545
23. Emery P., Sheeran T., Lehane P.B., Saiedabadi N., and Shaw T.M. Efficacy and safety of rituximab at 2 years following a single treatment in patients with active rheumatoid arthritis. Arthritis Rheum 50 Suppl. 9 (2005) S659
24. Edwards J.C., Leandro M.J., and Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 30 (2004) 393-403
25. Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50 (2004) 3580-3590
26. Roll P., Palanichamy A., Rouziere A.S., Dörner T., Kneitz C., and Tony H.P. B-cell regeneration after B cell depletion with rituximab in patients with rheumatoid arthritis: transient recirculation of plasmablasts and increased level of germinal center founder cell. Arthritis Rheum 52 Suppl. 9 (2005) S289
27. Leandro M.J., Cambridge G., Eherenstein M.R., and Edwards J.C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54 (2006) 613-620
28. Henneken M., Dörner T., Burmester G.R., and Berek C. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 7 (2005) R1001-R1013
29. Rouziere A.S., Kneitz C., Palanichamy A., Dörner T., and Tony H.P. Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res Ther 7 (2005) R714-R724
30. Szodoray P., Alex P., Dandapani V., Nakken B., Pesina J., Kim X., et al. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis. Scand J Immunol 60 (2004) 209-218
31. Baeklund E., Askling J., Rosenquist R., Ekbom A., and Klareskog L. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheum 16 (2004) 254-261
32. Quartuccio L, De Re V, Fabris M, Marzotto A, Franzolini N, Gasparotto D, et al. Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biologic agents: clinical course and molecular characterization. Haematologica in press.
33. Sarzi-Puttini P., Atzeni F., Capsoni F., Lubrano E., and Doria A. Drug-induced lupus erythematosus. Autoimmunity 38 (2005) 507-518